BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun 2022;13:4931. [PMID: 35995785 DOI: 10.1038/s41467-022-32551-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Basile A, Zannella C, De Marco M, Sanna G, Franci G, Galdiero M, Manzin A, De Laurenzi V, Chetta M, Rosati A, Turco MC, Marzullo L. Spike-mediated viral membrane fusion is inhibited by a specific anti-IFITM2 monoclonal antibody. Antiviral Res 2023;211:105546. [PMID: 36669656 DOI: 10.1016/j.antiviral.2023.105546] [Reference Citation Analysis]
2 Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser C, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S; Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight 2022;7:e163471. [PMID: 36378539 DOI: 10.1172/jci.insight.163471] [Reference Citation Analysis]
3 Zou J, Jing F. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19. Pharmaceuticals (Basel) 2022;15. [PMID: 36558922 DOI: 10.3390/ph15121472] [Reference Citation Analysis]
4 Zhu Q, Xu Y, Wang T, Xie F. Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. Front Immunol 2022;13:1053437. [PMID: 36505489 DOI: 10.3389/fimmu.2022.1053437] [Reference Citation Analysis]
5 Smith DM, Li JZ, Moser C, Yeh E, Currier JS, Chew KW, Hughes MD, Daar E, Wohl D, Eron J, Javan AC, Giganti M, Ritz J, Hosey L, Roa J, Patel N, Colsh K, Rwakazina I, Beck J, Seig S, Fletcher C, Fischer W, Evering T, Bender R, Cardoso S, Corado K, Jagannathan P, Jilg N, Perelson A, Pillay S, Riviere C, Singh U, Taiwo B, Gottesman J, Newell M, Pederson S, Dragavon J, Jennings C, Greenfelder B, Murtaugh W, Kosmyna J, Gapara M, Shahkolahi A, Kim P, Erhardt W, ACTIV-2/A5401 Study Team. Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19. JAMA Netw Open 2022;5:e2238867. [DOI: 10.1001/jamanetworkopen.2022.38867] [Reference Citation Analysis]
6 Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ, Smith D, Javan AC, Giganti M, Hosey L, Roa J, Patel N, Colsh K, Rwakazina I, Beck J, Sieg S, Fischer W, Evering T, Ignacio RB, Cardoso S, Corado K, Jagannathan P, Jilg N, Pillay S, Riviere C, Singh U, Taiwo B, Gottesman J, Newell M, Pedersen S, Dragavon J, Jennings C, Greenfelder B, Murtaugh W, Kosmyna J, Gapara M, Shahkolahi A, for the ACTIV-2/A5401 Study Team. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol 2022;7:1906-1917. [DOI: 10.1038/s41564-022-01254-1] [Reference Citation Analysis]